White label – Pompe disease - ClinicalTrials.eu

Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Recruiting

3 1 1 1
Investigated Drugs:
+2
Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression

Recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer metastatic
Investigated Drugs:
- Cemiplimab
- Pembrolizumab
Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Recruiting

3 1 1 1
Investigated Drugs:
- Fludarabine Phosphate
Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Recruiting

3 1 1
Investigated Diseases:
- Back pain
Investigated Drugs:
A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

Recruiting

3 1 1
Investigated Drugs:
- Fenfluramine Hydrochloride
+1
Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

Recruiting

1 1 1
Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

Recruiting

2 1 1
Investigated Drugs:
- Infigratinib
Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Recruiting

2 1 1 1
Investigated Diseases:
- Diffuse large B-cell lymphoma recurrent
- Diffuse large B-cell lymphoma refractory
Investigated Drugs:
Phase II Study of Intravenous Tarlatamab for Patients with Asymptomatic Brain Metastases from Small Cell Lung Cancer

Recruiting

2 1 1
Investigated Drugs:
- Tarlatamab
Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Recruiting

3 1 1
Investigated Drugs:
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies